logo-loader

RedHill Biopharma shows strong inhibition by opaganib of the coronavirus Delta variant

Published: 09:30 27 Aug 2021 EDT

RedHill Biopharma (NASDAQ:RDHL) Ltd (NASDAQ:RDHL) chief business officer Guy Goldberg caught up with Proactive New York to speak on results of its new preclinical study, which he says demonstrated strong inhibition by its investigational oral pill opaganib of the coronavirus Delta variant replication while maintaining cell viability at relevant concentrations.

Goldberg says opaganib was studied in a 3D tissue model of human bronchial epithelial cells (EpiAirway) to evaluate the in vitro efficacy of opaganib in inhibiting the Delta (Indian) variant. RedHill said this adds to the previously reported work that showed opaganib also inhibits Beta (South African) and Gamma (Brazilian) SARS-CoV-2 variants.

RedHill Biopharma confident about Covid 19 oral pill progress

Newsflow relating to Covid 19 vaccinations is plentiful, but what of potential treatments in the form of oral medication? Nasdaq-listed RedHill Biopharma (NASDAQ:RDHL) is involved in that search. As chief business officer Guy Goldberg explains to Proactive London's Sarah Lowther the company...

on 06/10/2021